Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans

Philip Carter, Costi Alifrangis, Biancastella Cereser, Pramodh Chandrasinghe, Lisa Del Bel Belluz, Nina Moderau, Fotini Poyia, Lee Schwartzberg, Neha Tabassum, Jinrui Wen, Jonathan Krell, Justin Stebbing

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We used data obtained by Caris Life Sciences, to evaluate the benefits of tailoring treatments for a breast carcinoma cohort by using tumor molecular profiles to inform decisions. Data for 92 breast cancer patients from the commercial Caris Molecular Intelligence database was retrospectively divided into two groups, so that the first always followed treatment recommendations, whereas in the second group all patients received at least one drug after profiling that was predicted to lack benefit. The biomarker and drug associations were based on tests including fluorescent in situ hybridization and DNA sequencing, although immunohistochemistry was the main test used. Patients whose drugs matched those recommended according to their tumor profile had an average overall survival of 667 days, compared to 510 days for patients that did not (P=0.0316). In the matched treatment group, 26% of patients were deceased by the last time of monitoring, whereas this was 41% in the unmatched group (P=0.1257). We therefore confirm the ability of tumor molecular profiling to improve survival of breast cancer patients. Immunohistochemistry biomarkers for the androgen, estrogen and progesterone receptors were found to be prognostic for survival.

Original languageEnglish (US)
Pages (from-to)17589-17596
Number of pages8
JournalOncotarget
Volume9
Issue number25
DOIs
StatePublished - Apr 1 2018

Fingerprint

Breast Neoplasms
Survival
Therapeutics
Biomarkers
Immunohistochemistry
Chemical Databases
Pharmaceutical Preparations
Neoplasms
Aptitude
Biological Science Disciplines
Androgen Receptors
Progesterone Receptors
Fluorescence In Situ Hybridization
Intelligence
DNA Sequence Analysis
Estrogen Receptors
Research Design

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Carter, P., Alifrangis, C., Cereser, B., Chandrasinghe, P., Belluz, L. D. B., Moderau, N., ... Stebbing, J. (2018). Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans. Oncotarget, 9(25), 17589-17596. https://doi.org/10.18632/oncotarget.24564

Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans. / Carter, Philip; Alifrangis, Costi; Cereser, Biancastella; Chandrasinghe, Pramodh; Belluz, Lisa Del Bel; Moderau, Nina; Poyia, Fotini; Schwartzberg, Lee; Tabassum, Neha; Wen, Jinrui; Krell, Jonathan; Stebbing, Justin.

In: Oncotarget, Vol. 9, No. 25, 01.04.2018, p. 17589-17596.

Research output: Contribution to journalArticle

Carter, P, Alifrangis, C, Cereser, B, Chandrasinghe, P, Belluz, LDB, Moderau, N, Poyia, F, Schwartzberg, L, Tabassum, N, Wen, J, Krell, J & Stebbing, J 2018, 'Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans', Oncotarget, vol. 9, no. 25, pp. 17589-17596. https://doi.org/10.18632/oncotarget.24564
Carter P, Alifrangis C, Cereser B, Chandrasinghe P, Belluz LDB, Moderau N et al. Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans. Oncotarget. 2018 Apr 1;9(25):17589-17596. https://doi.org/10.18632/oncotarget.24564
Carter, Philip ; Alifrangis, Costi ; Cereser, Biancastella ; Chandrasinghe, Pramodh ; Belluz, Lisa Del Bel ; Moderau, Nina ; Poyia, Fotini ; Schwartzberg, Lee ; Tabassum, Neha ; Wen, Jinrui ; Krell, Jonathan ; Stebbing, Justin. / Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans. In: Oncotarget. 2018 ; Vol. 9, No. 25. pp. 17589-17596.
@article{0ca6a03384b04adfa51992b9cbda61f4,
title = "Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans",
abstract = "We used data obtained by Caris Life Sciences, to evaluate the benefits of tailoring treatments for a breast carcinoma cohort by using tumor molecular profiles to inform decisions. Data for 92 breast cancer patients from the commercial Caris Molecular Intelligence database was retrospectively divided into two groups, so that the first always followed treatment recommendations, whereas in the second group all patients received at least one drug after profiling that was predicted to lack benefit. The biomarker and drug associations were based on tests including fluorescent in situ hybridization and DNA sequencing, although immunohistochemistry was the main test used. Patients whose drugs matched those recommended according to their tumor profile had an average overall survival of 667 days, compared to 510 days for patients that did not (P=0.0316). In the matched treatment group, 26{\%} of patients were deceased by the last time of monitoring, whereas this was 41{\%} in the unmatched group (P=0.1257). We therefore confirm the ability of tumor molecular profiling to improve survival of breast cancer patients. Immunohistochemistry biomarkers for the androgen, estrogen and progesterone receptors were found to be prognostic for survival.",
author = "Philip Carter and Costi Alifrangis and Biancastella Cereser and Pramodh Chandrasinghe and Belluz, {Lisa Del Bel} and Nina Moderau and Fotini Poyia and Lee Schwartzberg and Neha Tabassum and Jinrui Wen and Jonathan Krell and Justin Stebbing",
year = "2018",
month = "4",
day = "1",
doi = "10.18632/oncotarget.24564",
language = "English (US)",
volume = "9",
pages = "17589--17596",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "25",

}

TY - JOUR

T1 - Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans

AU - Carter, Philip

AU - Alifrangis, Costi

AU - Cereser, Biancastella

AU - Chandrasinghe, Pramodh

AU - Belluz, Lisa Del Bel

AU - Moderau, Nina

AU - Poyia, Fotini

AU - Schwartzberg, Lee

AU - Tabassum, Neha

AU - Wen, Jinrui

AU - Krell, Jonathan

AU - Stebbing, Justin

PY - 2018/4/1

Y1 - 2018/4/1

N2 - We used data obtained by Caris Life Sciences, to evaluate the benefits of tailoring treatments for a breast carcinoma cohort by using tumor molecular profiles to inform decisions. Data for 92 breast cancer patients from the commercial Caris Molecular Intelligence database was retrospectively divided into two groups, so that the first always followed treatment recommendations, whereas in the second group all patients received at least one drug after profiling that was predicted to lack benefit. The biomarker and drug associations were based on tests including fluorescent in situ hybridization and DNA sequencing, although immunohistochemistry was the main test used. Patients whose drugs matched those recommended according to their tumor profile had an average overall survival of 667 days, compared to 510 days for patients that did not (P=0.0316). In the matched treatment group, 26% of patients were deceased by the last time of monitoring, whereas this was 41% in the unmatched group (P=0.1257). We therefore confirm the ability of tumor molecular profiling to improve survival of breast cancer patients. Immunohistochemistry biomarkers for the androgen, estrogen and progesterone receptors were found to be prognostic for survival.

AB - We used data obtained by Caris Life Sciences, to evaluate the benefits of tailoring treatments for a breast carcinoma cohort by using tumor molecular profiles to inform decisions. Data for 92 breast cancer patients from the commercial Caris Molecular Intelligence database was retrospectively divided into two groups, so that the first always followed treatment recommendations, whereas in the second group all patients received at least one drug after profiling that was predicted to lack benefit. The biomarker and drug associations were based on tests including fluorescent in situ hybridization and DNA sequencing, although immunohistochemistry was the main test used. Patients whose drugs matched those recommended according to their tumor profile had an average overall survival of 667 days, compared to 510 days for patients that did not (P=0.0316). In the matched treatment group, 26% of patients were deceased by the last time of monitoring, whereas this was 41% in the unmatched group (P=0.1257). We therefore confirm the ability of tumor molecular profiling to improve survival of breast cancer patients. Immunohistochemistry biomarkers for the androgen, estrogen and progesterone receptors were found to be prognostic for survival.

UR - http://www.scopus.com/inward/record.url?scp=85044836163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044836163&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.24564

DO - 10.18632/oncotarget.24564

M3 - Article

AN - SCOPUS:85044836163

VL - 9

SP - 17589

EP - 17596

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 25

ER -